TICKERNERD
Menu
NBIXNBIXHealthcare · Drug Manufacturers - Specialty & Generic

NBIX Stock Forecast: Neurocrine Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$156
−0.22% on the day

The 27 Wall Street analysts covering Neurocrine Biosciences, Inc. hold a median 12-month price target of $215 — +37.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$15.9B
Ticker Nerd rank
89 / 100
Median analyst target
$215
Analysts covering
27
Revenue$959.0M+39.5% y/y
Operating income$153.0M
Net income$144.4M
Free cash flow$128.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.3%
1M
−3.5%
YTD
+10.1%
1Y
+8.8%
From 52W high
−15.8%
From 52W low
+26.9%
$123
$186
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NBIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurocrine Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
97
Volatility
96
Growth
92
Issuance
73
Momentum
68
Revisions
60
Accruals
30
Size
12

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (12): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NBIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NBIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$150$200$250Oct 25Jan 26Apr 26Jul 26NBIXHigh $253Median $215Low $164

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says27 analysts
23 Buy4 Hold0 Sell
Low $164Median $215High $253

The green dot is the last close — the median target sits +37.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 10 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Sept 2026Morgan StanleyMaintainsEqual-Weight$182 → $183
8 Sept 2026RBC CapitalReiteratesOutperform$198
3 Sept 2026CitigroupMaintainsBuy$249 → $253
13 Aug 2026Morgan StanleyMaintainsEqual-Weight$196 → $182
13 Aug 2026Morgan StanleyMaintainsEqual-Weight—
3 Aug 2026Canaccord GenuityMaintainsBuy$200 → $210
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Truist SecuritiesMaintainsBuy$200 → $213
3 Aug 2026Truist SecuritiesMaintainsBuy—
3 Aug 2026WedbushMaintainsOutperform—
3 Aug 2026WedbushMaintainsOutperform$185 → $194
31 July 2026Cantor FitzgeraldMaintainsOverweight$210 → $215
31 July 2026Cantor FitzgeraldMaintainsOverweight—
31 July 2026CitigroupMaintainsBuy—
31 July 2026CitigroupMaintainsBuy$246 → $249
31 July 2026GuggenheimMaintainsBuy$200 → $222
31 July 2026GuggenheimMaintainsBuy—
31 July 2026Morgan StanleyMaintainsEqual-Weight—
31 July 2026Morgan StanleyMaintainsEqual-Weight$193 → $196
31 July 2026NeedhamMaintainsBuy$200 → $204

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NBIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NBIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Neurocrine Biosciences, Inc. returned +8.8% against +17.5% for the S&P 500, dividends included.

NBIX vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26NBIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NBIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.7%
Analysts raising
8
Analysts cutting
4
Fundamentals

Neurocrine Biosciences, Inc. (NBIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
22.9×

Cheaper than 33% of US stocks

Price / sales
4.7×

Cheaper than 26% of US stocks

Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
17.5×

Cheaper than 18% of US stocks

Growth & margins
Revenue growth (YoY)
39.5%

Higher than 83% of US stocks

Earnings growth (YoY)
34.3%

Higher than 68% of US stocks

Gross margin
97.6%

Higher than 99% of US stocks

Operating margin
22.2%

Higher than 81% of US stocks

Net margin
20.9%

Higher than 83% of US stocks

Returns & dividend
Return on equity
22.1%

Higher than 83% of US stocks

Return on assets
11.7%

Higher than 94% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurocrine Biosciences, Inc. (NBIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurocrine Biosciences, Inc. has a market value of $15.9B and an enterprise value of $16.0B.

  • Revenue in the twelve months to 30 June 2026: $3.4B. The latest quarter grew 39.5% year on year.

  • Net income over the same four quarters: $705.5M, a 20.9% net margin.

  • Diluted earnings per share, trailing twelve months: $6.82.

  • Free cash flow in the twelve months to 30 June 2026: $870.4M, after $27.7M of capital spending.

  • Neurocrine Biosciences, Inc. spent $66.0M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 101.6M.

  • Trailing P/E: 22.9×; forward P/E: 13.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Neurocrine Biosciences, Inc. employs 2,500 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

NBIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
NBIXNeurocrine Biosciences, Inc.$15.9B
89
VTRSViatris, Inc.$19.0B
100
ELANElanco Animal Health, Inc.$11.6B
98
UTHRUnited Therapeutics Corp.$21.1B
82
ZTSZoetis, Inc.$30.2B
43
ALKSAlkermes Plc$7.6B
62
LNTHLantheus Holdings, Inc.$6.5B
88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurocrine Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NBIX news & analysis

Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha · 10 Sept 2026neutral

Neurocrine Biosciences presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the conference event.

Why it matters — A NBIX watcher would care because the conference presentation provides an opportunity to hear management's discussion of the company's business and pipeline in a public forum.

Neurocrine Biosciences, Inc. (NBIX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha · 9 Sept 2026neutral

Neurocrine Biosciences presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation and remarks at the investor conference.

Why it matters — A NBIX watcher would care because the conference presentation offers insight into the company's business and strategy as communicated to investors and analysts.

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

PRNewsWire · 2 Sept 2026neutral

Neurocrine Biosciences announced that its executives will participate in the Wells Fargo 21st Annual Healthcare Conference in September. The company made this announcement in a press release dated Sept. 2, 2026.

Why it matters — Investors and analysts tracking NBIX may gain insight into the company's strategy through executive presentations at a major healthcare investor conference.

Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?

Zacks Investment Research · 31 Aug 2026positive

Neurocrine's Crenessity is gaining rapid traction in congenital adrenal hyperplasia (CAH), with sales soaring and low patient penetration leaving room for further growth.

Why it matters — A NBIX watcher would care because strong early sales of Crenessity in CAH, combined with low patient penetration, signals substantial untapped growth potential for the product.

NBIX vs. TEVA: Which Drugmaker Is the Better Investment?

Zacks Investment Research · 25 Aug 2026positive

Zacks Investment Research compared Neurocrine Biosciences with Teva, concluding that Neurocrine is the stronger investment pick due to strong Ingrezza growth, Crenessity momentum, and an expanding pipeline, despite noted valuation risks.

Why it matters — The article highlights Neurocrine's growth drivers and pipeline progress, offering NBIX watchers a positive view of the company's competitive position versus a major peer.

FAQ

Frequently asked questions about NBIX stock

What is the NBIX stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Neurocrine Biosciences, Inc. have a median 12-month price target of $215, with estimates ranging from $164 to $253. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NBIX stock a buy right now?

Of the 27 analysts covering Neurocrine Biosciences, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurocrine Biosciences, Inc. 89 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NBIX?

As at 12 Sept 2026, Neurocrine Biosciences, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will NBIX stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +37.6% from the last close, and Ticker Nerd's factor model ranks Neurocrine Biosciences, Inc. 89 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NBIX stock forecast for 2030?

No analyst covering Neurocrine Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NBIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $164 to $253 over the next 12 months.

How has NBIX stock performed over the past year?

Neurocrine Biosciences, Inc. returned +8.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders.

What is the latest news on NBIX?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "Neurocrine Biosciences, Inc. (NBIX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript". Neurocrine Biosciences presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item reports on the company's participation in the conference event.

Company

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric disorders. Its current portfolio includes treatments for movement disorders such as tardive dyskinesia and Huntington’s disease chorea, as well as therapies for endocrine conditions including congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also maintains a clinical-stage pipeline spanning additional neuroscience and endocrine targets, with research programs aimed at addressing underserved patient populations. Neurocrine Biosciences, Inc. plays an important role in specialty pharmaceuticals by combining marketed products with ongoing drug development across complex, chronic conditions that often require long-term management. Headquartered in San Diego, California, it serves patients and healthcare providers in the United States and internationally through its commercial operations and development activities.

CEO Mr. Kyle W. Gano Ph.D. · 2,500 employees · United States · https://www.neurocrine.com